biological source
mouse
conjugate
unconjugated
antibody form
ascites fluid
clone
DCS-50, monoclonal
mol wt
antigen 16 kDa
contains
15 mM sodium azide
species reactivity
human
technique(s)
immunocytochemistry: suitable, immunohistochemistry (frozen sections): suitable, immunoprecipitation (IP): suitable, indirect ELISA: suitable, microarray: suitable, western blot: 1:1,000 using a cultured human tumor cell line extract
isotype
IgG1
shipped in
dry ice
storage temp.
−20°C
Gene Information
human ... CDKN2A(1029)
Immunogen
recombinant human p16 protein.
Biochem/physiol Actions
The antibody reacts specifically with the C-terminal (last 12 amino acids) of human p16 molecule (also known as p16INK4, p16INK4a, p16MTS1, inhibitor of CDK4). An additional application for this antibody is microinjection into cells.
法规信息
新产品
此项目有
J Lukas et al.
Cancer research, 55(21), 4818-4823 (1995-11-01)
The p16INK4/CDKN2, D-type cyclins, their partner cyclin-dependent kinases, and retinoblastoma protein constitute a G1 regulatory pathway commonly targeted in oncogenesis. We show that, unexpectedly, abnormalities of p16INK4/CDKN2 occur concomitantly in two-thirds of cancer cell lines harboring aberrations of cyclin D1.
J Lukas et al.
Nature, 375(6531), 503-506 (1995-06-08)
D-type cyclins, in association with the cyclin-dependent kinases Cdk4 or Cdk6, promote progression through the G1 phase of the cell cycle by phosphorylating the retinoblastoma protein (RB). The activities of Cdk4 and Cdk6 are constrained by inhibitors such as p16
A L Reed et al.
Cancer research, 56(16), 3630-3633 (1996-08-15)
The tumor suppressor gene p16 (CDKN2/MTS-1/INK4A) can be inactivated by multiple genetic mechanisms. We analyzed 29 invasive primary head and neck squamous cell carcinomas (HNSCC) for p16 inactivation with immunohistochemistry utilizing a new monoclonal antibody (mAb), DCS-50. p16 staining of
Therese M Becker et al.
International journal of cancer, 117(4), 569-573 (2005-06-10)
Melanoma-associated germline mutations affecting the tumor suppressor and cyclin-dependent kinase (CDK) inhibitor, CDKN2A/p16INK4a, have been identified in over 100 melanoma-prone families worldwide. To predict the melanoma risk for carriers of specific mutations, mutant p16INK4a can be tested in biochemical and
L Aagaard et al.
International journal of cancer, 61(1), 115-120 (1995-03-29)
The p16Ink4/MTS1/CDKN2 is a cell-cycle regulatory inhibitor of cyclin-dependent kinase 4 (cdk4), and a candidate tumour suppressor whose gene on chromosome band 9p21 is frequently deleted or mutated in diverse types of cancer. Cdk4 in association with its D-type cyclin
相关内容
Datasheet
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持